Triple therapy with methotrexate, sulfasalazine, and hydroxychloroquine in patients with rheumatoid arthritis.
Combinations of DMARDs are currently used to treat rheumatoid arthritis by almost all rheumatologists. This article reviews the published data on the triple combination of methotrexate, sulfasalazine, and hydroxychloroquine, discusses caveats for clinical use, compares efficacy of different combinations, and speculates on future combination therapies.
Department of Medicine, University of Nebraska Medical Center, Omaha, USA.
J R
JR
O'Dell
D018501:Antirheumatic Agents / Q000008:administration & dosage*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D016572:Cyclosporine / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D006801:Humans; D006886:Hydroxychloroquine / Q000008:administration & dosage*; D008727:Methotrexate / Q000008:administration & dosage*; D012460:Sulfasalazine / Q000008:administration & dosage*; D016896:Treatment Outcome
D018501:Antirheumatic Agents; D012460:Sulfasalazine; D006886:Hydroxychloroquine; D016572:Cyclosporine; D008727:Methotrexate